Radio-frequency generator for powering an ablation device

Information

  • Patent Grant
  • 9554853
  • Patent Number
    9,554,853
  • Date Filed
    Friday, October 4, 2013
    11 years ago
  • Date Issued
    Tuesday, January 31, 2017
    8 years ago
Abstract
An apparatus and method for use in performing ablation of organs and other tissues includes a radio frequency generator which provides a radio frequency signal to ablation electrodes. The power level of the radio frequency signal is determined based on the subject area of ablation. The radio frequency signal is coupled with the ablation electrodes through a transformation circuit. The transformation circuit includes a high impedance transformation circuit and a low impedance transformation circuit. The high or low impedance transformation circuit is selected based on the impedance of the ablation electrodes in contact with the subject tissue. Vacuum level, impedance level, resistance level, and time are measured during ablation. If these parameters exceed determinable limits the ablation procedure is terminated.
Description
TECHNICAL FIELD OF THE INVENTION

The present invention relates generally to the ablation of tissue and more specifically to an apparatus and method for providing radio-frequency power to an ablation device.


BACKGROUND

Ablation of the interior lining of a body organ is a procedure which involves heating the organ lining to temperatures which destroy the cells of the lining or coagulate tissue proteins for hemostasis. Such a procedure may be performed as a treatment to one of many conditions, such as chronic bleeding of the endometrial layer of the uterus or abnormalities of the mucosal layer of the gallbladder. Existing methods for effecting ablation include circulation of heated fluid inside the organ (either directly or inside a balloon), laser treatment of the organ lining, and resistive heating using application of radio-frequency (RF) energy to the tissue to be ablated.


Techniques using RF energy provide an RF electrical signal to one or more electrodes in contact with the subject organ tissue. Electrical current flows from the electrodes and into the organ tissue. The current flow resistively heats the surrounding tissue. Eventually, the heating process destroys the cells surrounding the electrodes and thereby effectuates ablation.


Before the start of power delivery, blood and saline solution may surround the electrodes. As the cells surrounding the electrodes are destroyed, additional blood and saline solution will surround the electrodes. These conductive liquids act to decrease the electrode impedance. These liquids may be suctioned away during the ablation process. Absent these conductive liquids, the electrode impedance will increase with the destruction of the surrounding cells. Depending upon the specific electrode configuration, the impedance characteristics may change from as little as a fraction of an ohm to well over 200 ohms during the course of an ablation procedure.


The RF ablation technique must be performed using great care to prevent over-ablation. Monitoring of tissue surface temperature is normally carried out during these ablation procedures to ensure the temperature does not exceed 100° C. If the temperature exceeds 100° C., the fluid within the tissue begins to boil and to thereby produce steam. Because ablation is carried out within a closed cavity within the body, the steam cannot escape and may instead force itself deeply into the tissue, or it may pass into areas adjacent to the area intended to be ablated, causing embolism or unintended burning of adjacent tissues.


An RF ablation device must accurately determine the appropriate level of power. This power level must provide sufficient heating to effectuate ablation. At the same time, the power level must be controlled to prevent over-ablation. Moreover, an RF generator must be controlled to respond dynamically to changes in the impedance of the subject tissue.


Existing RF ablation devices generally apply power to electrodes having a relatively small surface area (e.g. forcept electrodes). Such electrodes ablate a relatively small surface area at a relatively high impedance. Accordingly, the required RF power is relatively low and simple to deliver (typically 80 Watts at approximately 100 Ohms). During an ablation procedure, the impedance characteristics of such electrodes may change. However, many generators are suitable for providing the relatively low power level over a range of high impedances.


To ablate a large tissue area with electrodes having a relatively small surface area, an operator must move electrodes about the tissue surface. This introduces a measure of imprecision. An electrode matched to the surface area of the subject tissue reduces this imprecision. However, matching the electrode area to the subject tissue area significantly increases the surface area of the electrode. Accordingly, the electrode requires significantly greater power levels to effect ablation. Moreover, relatively large surface areas are characterized by a relatively low initial impedance, which increases significantly during the course of an ablation.


It is therefore desirable to provide a power level sufficient to effectuate ablation on a relatively large surface area electrode. The power level, however, must not result in over-ablation. It is also desirable to dynamically control the RF generator to respond to impedance changes within the subject organ tissue. It is further desirable to provide an ablation method and device which allows the depth of ablation to be controlled reliably and which automatically discontinues ablation once the desired ablation depth has been reached.


BRIEF SUMMARY

An apparatus and method for use in performing ablation of organs and other tissues includes an RF generator configured to provide an RF signal to ablation electrodes. The power level of the RF signal is determined based on the subject area and depth of the volumetric ablation. The RF signal is coupled with the ablation electrode through a transformation circuit. The transformation circuit includes a low impedance and a high impedance transformation circuit. The low impedance and high impedance transformation circuits are selected based on the impedance of the ablation electrode in contact with the subject tissue. Vacuum level, impedance level, resistance level, and time are measured during ablation. If these parameters exceed determinable limits the ablation procedure is terminated.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a side elevation view of an RF generator according to the invention and an ablation device suitable for use with the RF generator.



FIG. 1B is a top view of the distal end of the ablation device of FIG. 1A, shown with an applicator head in an extended position.



FIG. 1C is a perspective view of the applicator head in the extended position of FIG. 1B.



FIG. 1D is a front elevational view of the applicator head in the extended position of FIG. 1B.



FIG. 2 is a circuit block diagram of the RF generator of FIG. 1.



FIG. 3 is a circuit block diagram of the controller of FIG. 2, including additional circuit elements connected with the controller.



FIG. 4 is a circuit block diagram of the auto-switch circuit of FIG. 2, including additional circuit elements connected with the auto-switch circuit.



FIG. 5 is a circuit block diagram of the display board of FIG. 2, including additional circuit elements connected with the display board.



FIG. 6 is a circuit diagram of one preferred embodiment of the transformer circuit of FIG. 5 connected with a regulator and a filter network.



FIG. 7 is a circuit diagram of another embodiment of the transformer circuit of FIG. 5.



FIG. 8 is a flow chart showing the operation of an RF generator according to the invention.



FIG. 9 is a flow chart showing the operation of an the auto-switch circuit according to the invention.





DETAILED DESCRIPTION

Referring to FIGS. 1A and 1B, an intrauterine ablation device 100 suitable for use with an RF generator 116 according to the present invention is comprised generally of three major components: an RF applicator head 103, a sheath 105, and a handle 106. The applicator head 103 is slidably disposed within the sheath 105 (FIG. 1A) during insertion of the device into the uterine cavity, and the handle 106 is subsequently manipulated as indicated by arrow A1 to cause the applicator head 103 to extend from the distal end of the sheath 105 (FIG. 1B).


Referring to FIG. 1B, applicator head 103 extends from the distal end of a length of tubing 108 which is slidably disposed within the sheath 105. Applicator 103 includes an external electrode array 103a and an internal deflecting mechanism 103b used to expand the array for positioning into contact with the tissue.


The RF electrode array 103a is formed of a stretchable metallized fabric mesh which is preferably knitted from a nylon and spandex knit plated with gold or other conductive material. Insulating regions 140 (FIGS. 1C, 1D) are formed on the applicator head to divide the mesh into electrode regions. The insulated regions 140 are preferably formed using etching techniques to remove the conductive metal from the mesh, although alternate methods may also be used, such as by knitting conductive and non-conductive materials together to form the array.


The array may be divided by the insulated regions 140 into a variety of electrode configurations. In a preferred configuration (FIG. 1C) the insulating regions 140 divide the applicator head into four electrodes 142a-142d by creating two electrodes on each of the broad faces 134. To create this four-electrode pattern, insulating regions 140 are placed longitudinally along each of the broad faces 134 as well as along the length of each of the faces 136, 138. The electrodes 142a-142d are used for ablation and, if desired, to measure tissue impedance during use.


Deflecting mechanism 103b and its deployment structure is enclosed within electrode array 103a. Referring to FIG. 1B, external hypotube 109 extends from tubing 108 and an internal hypotube 110 is slidably and co-axially disposed within hypotube 109. Flexures 112 extend from the tubing 108 on opposite sides of hypotube 109. A plurality of longitudinally spaced apertures (not shown) may be formed in each flexure 112. During use, these apertures allow moisture to pass through the flexures and to be drawn into exposed distal end of hypotube 109 using a vacuum source 140 fluidly coupled to hypotube 109 at vacuum port 138.


Internal flexures 116 extend laterally and longitudinally from the exterior surface of hypotube 110 and are each connected to a corresponding one of the flexures 112. A transverse ribbon 118 extends between the distal portions of the internal flexures 116. Transverse ribbon 118 is preferably pre-shaped such that when in the relaxed condition the ribbon assumes the corrugated configuration shown in FIG. 1B and such that when in a compressed condition it is folded along the plurality of creases 120 that extend along its length.


The deflecting mechanism 103b formed by the flexures 112, 116, and ribbon 118 shapes the array 103a into the substantially triangular shape shown in FIG. 1B, which is particularly adaptable to most uterine shapes. During use, distal and proximal grips 144, 146 forming handle 106 are squeezed towards one another to deploy the array. This action results in relative rearward motion of the hypotube 109 and relative forward motion of the hypotube 110. The relative motion between the hypotubes causes deflection in flexures 112, 116 which deploys and tensions the electrode array 103a.


Flexures 112, 116 and ribbon are preferably made from an insulated spring material such as heat treated 17-7 PH stainless steel. Each flexure 112 preferably includes conductive regions that are electrically coupled to the array for delivery of RF energy to the body tissue. Strands of thread 145 (which may be nylon) are preferably sewn through the array 103 and around the flexures 112 in order to prevent the conductive regions 132 from slipping out of alignment with the electrodes 142a-142d.


As will be discussed in detail below, the RF generator system according to the present invention utilizes an ablation power that is selected based on the surface area of the target ablation tissue. For uterine ablation, the RF power is calculated using the measured length and width of the uterus. These measurements may be made using conventional intrauterine measurement devices.


Alternatively, the ablation device 100 itself may be used to measure the uterine width by transducing the separation of flexures using a mechanical or electrical transducing means. Referring again to FIG. 1B, the ablation device 100 includes non-conductive (e.g. nylon) suturing threads 122 that extend between the hypotube 110 and the distal portion of the deflecting mechanism (FIG. 1B). Threads 122 are connected to an elongate wire (not shown) which extends through the tubing and is coupled to a mechanical transducer such as a rotatable bobbin (not shown) or an electrical transducer such as a strain gauge electrically coupled to an A/D converter to electrically transduce the separation distance of the flexures 112 and to electronically transmit the uterine width to a visual display and/or directly to the RF generator.


Turning to FIG. 2, one preferred embodiment of an RF generator circuit is described. The circuit includes a power supply 200. The power supply 200 accepts an AC signal and generates a 36 volt DC signal at up to 10 amps. The power supply 200 connects to converters 202, 204, 206, and 208. The converters 202, 204, 206, and 208 generate +5, +12, −12, and +24 volt electric potentials, respectively. As needed, the converters 202, 204, 206, and 208 provide the electric potentials to various circuit components hereinafter described.


A display board 212 generally provides a user interface. This interface allows a user to input selection data and provides feedback information. The display board 212 provides a digital signal indicating a desired power setting to digital-to-analog (D/A) converter 214. The D/A converter 214 converts the incoming digital signal into a voltage potential. This voltage potential (PSET), representing the desired power setting, is provided to an error amplifier 216. The error amplifier 216 also receives a voltage potential representing the actual power (PACT) currently delivered to an ablation device. The error amplifier compares the set power signal to the actual power signal to determine whether output power should be increased or decreased. If the set power signal is greater than the actual power signal, the error amplifier 216 provides a positive signal to the regulator 210. In response, the regulator 210 increases the output power. If the set power signal is less than the actual power signal, the error amplifier 216 provides a negative signal to the regulator 210. In response, the regulator 210 decreases the output power.


The regulator 210 receives DC power from the power supply 200 and provides a RF signal to FET switch 211. The signal from the error amplifier 216 controls the pulse width modulation of the regulator 210. Pulse width increases effect an increase in power; pulse width decreases effect a decrease in power.


The FET switch 211 receives the RF signal from the regulator 210. The FET switch also receives a control signal from the controller 218. When energized, the control signal turns on the FET switch 211 so that the RF signal is provided to auto-switch circuit 230. When de-energized, the control signal turns off the FET switch 211 so that any signal provided by the regulator 210 is disconnected from the auto-switch circuit 230.


The auto-switch circuit 230 also receives control signals from the controller 218, and an impedance signal from the divider 222. Based on the control and impedance signals, the auto-switch circuit 230 selects between a low impedance and a high impedance transformation circuits 440 (FIG. 4). The output of the selected transformer circuit is provided to the filter network 232. The filter network 232 acts as a bandpass filter having a preferred center frequency of approximately 482 KHz. The filter network 232 reduces any higher-order harmonic signals on the RF signal. In addition, the filter network 232 decouples any DC components from the regulator 210.


Current detector 234 measures the current provided through the filter network 232. Similarly, the voltage detector 236 measures the voltage provided across the output of the filter network 232. These measured signals are provided to the divider 222 through RMS converters 221 and 222. The measured signals are also provided to the multiplier 220. The divider 222 divides the voltage signal by the current signal to produce a signal representing the effective impedance of an ablation device. The multiplier 220 multiplies the voltage signal by the current signal to produce a signal representing the actual power provided to an ablation device. As described above, the actual power signal is used by the error amplifier 216 to control the regulator 210. The effective impedance signal is used by the auto-switch circuit 230 to select between the low impedance and high impedance transformation circuit.


The actual power signal (PACT) from multiplier 220 and the effective impedance signal from divider 222 are both provided to the controller 218. The controller 218 also connects to the set power signal input of the error amplifier 116. The controller 218 is configured to measure the power set signal and to generate a set power signal. During an ablation procedure, if the controller 218 detects a terminal fault condition, the controller 218 drives the set power signal to zero and de-energizes the FET switch 211. Driving the set power signal to zero causes the regulator 210 to turn off the RF signal.


The RF generator also includes a DC resistance detector 238 connected across output relays 240. The DC resistance detector 238 measures the DC resistance of an external ablation device. The DC resistance detector 238 provides a signal related to this resistance to the controller 218. The controller uses this signal to detect a short circuit in an attached ablation device.


The output relays 240 receive the filtered RF signal from the filter network 232. The output relays 240 are configured to provide this signal to the output terminals 242 in response to a control signal from the controller 218. When energized, the output relays 240 connect the RF generator circuit to an ablation device through output terminals 242. When de-energized, the output relays 240 isolate the RF generator circuit from an ablation device.


Turning to FIG. 3, a preferred embodiment of the controller 218 and additional related components are described. A fault and steering control block 302 of the controller 218 provides control signals to the display board 212, the FET switch 211, the auto-switch circuit 230, and the output relays 240.


The controller 218 provides the impedance signal from divider 222 (FIG. 2) to both an audio circuit 310 and a data I/O translator 306. The audio circuit 310 produces a frequency signal related to the impedance signal. Low impedances are transduced into higher frequency signals; high impedances are transduced into a lower frequency signals. The frequency signal lies within the range of audible frequencies and is used to drive a speaker 312. During the process of ablation, the measured impedance will increase. Accordingly, the frequency of the sound signal produced by the speaker 312 will decrease. This provides audible feedback of the ablation process to an operator. The audio circuit 310 may also be configured to provide signals that increase in frequency with increased impedance.


The controller 218 also provides the actual and set power signals and the vacuum signal to the data I/O translator 306. The data I/O translator converts these signals and the impedance signal into a related digital signal, which is provided over an RS232 connection 308.


Vacuum pump AC switch 314 is controlled by the controller 218. When activated, the pump AC switch connects AC power to a vacuum pump 316, which draws moisture from the ablation device and surrounding tissue. When deactivated, pump AC switch disconnects AC power from the vacuum pump 316. The vacuum pump 316 also includes a pressure transducer 318. The pressure transducer 318 is configured to measure the pressure induced within an ablation device. The pressure transducer 318 provides a signal representing this pressure to the controller 218, which monitors whether suction applied by the vacuum pump 316 is within determined limits.


Turning to FIG. 4, a preferred embodiment of the auto-switch circuit 230 is shown. The auto-switch circuit includes a control sequence PAL 400. The PAL 400 receives timer, impedance, and ready signals from controller 218. When activated, the timer signal indicates that the duration of the ablation has exceeded 120 seconds; the impedance signal indicates that the impedance of the ablation device exceeds 50 ohms; and the ready signal indicates that an operator has engaged an RF enable switch.


The impedance signal from the divider 222 (FIG. 2) is also provided to a comparator 420 via controller 218. If the impedance is greater than 10 ohms, the comparator 420 activates a signal to delay 430. If the impedance is less than 6 ohms, the comparator 420 activates a signal to delay 432. The delays 430 and 432 also receive a clock signal from controller 218. If either of the delays 430 or 432 continue to receive a signal from the comparators for more than five seconds, the respective delay activates a signal to the PAL 400. When the impedance is greater than 10 ohms for longer than five seconds, the PAL 400 provides a switch taps (SWTAPS) signal to the transformer circuit 440 selecting a high impedance transformation circuit. When the impedance is less than 6 ohms for longer than 5 seconds, the PAL selects a low impedance transformation circuit.


The controller 218 also provides an RF power on (RFON) signal to delay 434 and timer 436. If this signal remains active for greater than five seconds, delay 434 activates a power on self test (POST) signal to PAL 400. In addition to the RFON signal, timer 436 also receives a clear timer (CLRTMS) signal from the PAL 400. The CLRTMS signal is activated upon a change of state in the SWTAPS signal and indicates that the transformer circuit has changed to match the impedance of the ablation device. Upon receiving either the RFON or the SWTAPS signal, the timer 436 resets a short and a long timer. After expiration of the short timer, the timer 436 activates the short timer signal, which is provided to the PAL 400. After expiration of the long timer, the timer 436 activates the long timer, which is also provided to PAL 400. These signals are used by the PAL 400 to generate condition signals. The condition signals are used in conjunction with fault signals to determine whether to terminate an ablation procedure.


The transformation circuit 440 is connected between the FET switch 211 and the output filter network 232 (FIG. 2). The transformation circuit 440 operates to match the impedance of the regulator 210 to that of an ablation device. Again, the impedance of an ablation electrode in contact with the subject tissue may change significantly during the course of an ablation. By matching the impedance of regulator 210 to that of the electrode, the regulator 210 is able to deliver a relatively constant power level. This in turn allows accurate and uniform ablation.


Alternatively, if the impedance of a regulator were matched to a low electrode impedance then the regulator's power delivery will decline as the electrode impedance increases. If the impedance of the regulator were instead matched to a high electrode impedance then at a low initial electrode impedance the regulator will bear a high current load. This load may cause damage or heating to regulator components.


Accordingly, the transformation circuit 440 include a low impedance transformation circuit and a high impedance transformation circuit. A preferred low impedance transformation circuit matches the impedance of the regulator 210 to a three ohm load. A preferred high impedance transformation circuit matches the impedance of the regulator 210 to a twenty-five ohm load. These transformation circuits allow a regulator to provide relatively constant power delivery.


Again, the PAL 400 provides condition signals to the controller 218. Specifically, the PAL 400 generates a GENFAULT, an IGVAC, an ILPF and a PTEST signal. The GENFAULT signal indicates that the PAL has detected a fault condition and that the ablation should be terminated. The IGVAC signal indicates that the vacuum circuit has just been energized. Accordingly, any vacuum faults should be ignored for 2 seconds while the vacuum pump establishes the appropriate pressure. The IPLF signal indicates that any low priority faults should be ignored. The IPLF signal is activated during start up so that non-critical transient faults do not terminate the ablation procedure. The PTEST indicates that a low-level RF signal is currently being applied to the transformation circuit. The low-level RF signal is used to measure RF impedance before applying full power.


Turning to FIG. 5, the display board 212 of FIG. 2 and additional related components are described. The display board 212 connects to length and width selection switches 502. After determining the length and width of a subject uterine cavity, an operator enters the appropriate settings using switches 502. The length and width selections are shown on displays 508 and 510, respectively. To increase the width, an operator engages the up arrow switch 550. To decreases the width, an operator engages the down arrow switch 552. To increase the length, an operator engages the up arrow switch 560. To decrease the length, an operator engages the down arrow switch 562. A signal indicating the length and width are provided to the EPROM 516. The EPROM 516 converts the length and width to a set power level according to the following relationship:

P=L×W×5.5

Where P is the power level in Watts, L is the length in centimeters, W is the width in centimeters, and 5.5 is a constant having units of Watts per square centimeter.


The display board 212 also provides a signal to a set power display 506. This signal is determined based on the length and width selections so that the set power display 506 shows the current power setting.


After an operator selects an appropriate length and width setting, he or she engages the ready switch 504. The ready switch 504 provides a signal to the display board 212, which is in turn provided to the controller 218. The ready switch 504 indicates that the operator is ready to begin an ablation procedure.


After an operator engages the ready switch 504, the operator may then depress foot pedal 512. The foot pedal 512 connects to foot switch 514 to provide a signal to the display board 212, which is also provided to the controller 218. This signal indicates that the RF generator should apply RF power to an ablation device.


The display board 212 also connects to status LED's including a READY 320, RF OFF 322, HIGH Z 324, LOW Z 326, HIGH VAC 328, LOW VAC 340, and RF ON 342. The display board 212 controls these LED's based on signals received from the controller 218 and from the user inputs.


The READY LED 520 indicates that the RF generator is in a ready condition, and that activation of the foot switch 514 would activate RF power. The RF OFF LED 522 indicates that a DC short condition exists with the ablation device currently connected to the RF generator and that the RF generator is not currently providing power to an ablation device. The HIGH Z LED 524 indicates that the impedance exceeds a determined level. When this condition occurs, the controller automatically terminates ablation. The LOW Z LED 526 indicates that the impedance falls below a determined level. When this condition occurs, an RF short condition exists. The HIGH VAC LED 528 indicates that the vacuum pump 140 is currently exceeding determined acceptable vacuum levels. For example, this condition may be generated by an operator standing on the suction tubes connecting the vacuum pump 140 to port 138. The LOW VAC LED 540 indicates that the vacuum pump 140 is currently below an acceptable vacuum level. For example, this condition may be generated if the vacuum pump 140 were not properly attached to port 138. The RF ON LED 542 indicates that the RF generator is currently providing power to an ablation device.


Turning to FIG. 6, a preferred embodiment of a regulator 210, FET switch 211, transformation circuit 440, and output filter network 230 are shown. The transformation circuit 440 includes a transformer 605 having a power winding 610 and a load winding 620. The power winding 610 connects to FET switch 211 for receiving RF power from the regulator 210. The load winding 620 is electromagnetically coupled with power winding 610. Accordingly, electric power provided to the power winding 610 is transferred to the load winding 620.


The load winding 620 includes a center tap 626 which divides the load winding into a first portion 622 and a second portion 624. Switch 630 selects between the center tap 626 and an exterior tap 627. Selection of the center tap 626 provides a circuit matched to a lower impedance. Selection of the exterior tap 627 provides a circuit matched to a higher impedance. Alternatively stated, the switch 630 selects the transformation ratio between the power winding 610 and the output terminals 642. The output terminals 642 connect to an output filter network 232 having the above described bandpass characteristics.


Turning to FIG. 7, an alternative embodiment of a transformation circuit is shown. The transformation circuit 740 includes a first transformer 705 having a power winding 710 and a load winding 720. The transformer switch circuit also includes a second transformer 706 having a power winding 712 and a load winding 722. The transformation ratio of the first transformer 705 is matched to a low impedance. The transformation ratio of the second transformer 706 is matched to a high impedance.


Switch 730 is connected to select between the first transformer 705 and the second transformer 706. As shown, the switch 730 selects the first transformer 705 to electrically couple input terminals 740 to output terminals 742. The switch may also select the second transformer 706 to electrically couple input terminals 740 to output terminals 742.


Turning to FIG. 8, a flow chart showing the preferred operation of an RF generator used to power an ablation device is illustrated. At block 810, an operator selects a length and width related to the size of the subject uterus and activates a ready switch.


At block 812, the RF generator measures DC resistance through the ablation device. A measured resistance below 200 ohms indicates a short circuit. If a short circuit is detected, the RE generator will provide an indication to the operator and terminate the procedure. A measured resistance greater than 200 ohms indicates acceptable contact of the ablation device with the subject uterus. At block 811, the operator may then activate a foot-switch to apply power to an RF regulator.


At block 814, the RF generator applies power to a vacuum pump. After a few seconds, the pressure within the subject uterus will drop.


At block 816, the RF generator applies a low-level RF signal (e.g. between 5 and 10 Watts) to the ablation device. At block 820, the RF generator tests for faults which indicate that the procedure should be terminated. Specifically, the RE generator continues to test the DC resistance. The RF generator also tests whether the RE impedance falls within acceptable limits (e.g. 0.5-50 ohms), and whether the vacuum level falls within acceptable limits. During the first few seconds (e.g. 2 seconds) these faults may be ignored, as the transient characteristics may exceed fault tolerances.


If the RF generator does not detect any faults, it proceeds to block 822. Here, the RF generator applies full power to the ablation device. At the beginning of the ablation procedure, the power level may be gradually increased to the full power setting. At block 823, the RF generator tests whether the impedance of the subject uterus has exceeded fifty ohms or if the duration of the ablation has exceeded 120 seconds. If ether of these events occur, the ablation is complete and the procedure is terminated at block 824. Otherwise, the RE generator continues to test for faults at block 820. Upon detection of a fault the procedure is similarly terminated and power to the ablation device is disabled.


The process of applying power as shown at block 822 will now be discussed in greater detail. Turning to FIG. 9, a flow chart showing the preferred operation of the application of power through a transformation circuit is illustrated. The transformation circuit is used to couple power supplied by the RE generator to an ablation device. As described above, a preferred transformation circuit includes a low impedance transformation circuit and a high impedance transformation circuit. The operation of the transformation circuit begins at block 910, where the low impedance transformation circuit is selected. At block 911, a low level RF signal is applied to the transformation circuit.


At block 912, the impedance of an ablation device is measured. If the impedance has not exceeded 10 ohms for 5 seconds the process returns to block 911. Here, the pulse width of the RF signal will increase until it reaches the selected power level. Upon reaching the selected level, the pulse width is controlled according to changes in the electrode impedance to maintain a constant power level.


The process again returns to block 912 where the impedance of the ablation device is again measured. In the preferred embodiment, if the impedance exceeds 10 ohms for 5 seconds, the process proceeds to block 913. Here, the pulse width of the RF signal must be decreased so that the transformation circuit may switch from the low impedance transformation circuit to the high impedance transformation circuit.


At block 914, after reducing the RF signal to a low level, the switch changes states to select the high impedance transformation circuit. At block 915, power is then ramped back up to the selected level. This reduction in power and gradual increase reduces transient spikes which might result from the switching between the low impedance transformation circuit and the high impedance transformation circuit.


At block 916, the impedance of the ablation device is measured. If the impedance has not dropped below 6 ohms for 5 seconds, the process returns to block 915. Here, the pulse width is controlled to deliver the selected power level.


The process again returns to block 916 where the impedance of the ablation device is again measured. In the preferred embodiment, if the impedance drops below 6 ohms for 5 seconds, the process proceeds to block 917. Here, the pulse width of the RF signal must be decreased so that the transformation circuit may switch from the high impedance transformation circuit to the low impedance transformation circuit at block 910. The operation of the transformation circuit continues in this manner until the ablation is terminated. At termination, the power is turned off and the RF generator is disconnected from the ablation device.


Although the forgoing description is with reference to the ablation of a uterus, the present invention is applicable to the ablation of other body tissues. In addition, although the RF generator is described with reference to a particular circuit many other configurations are suitable for implementing the teachings of the invention. Those having ordinary skill in the art will certainly understand from the embodiments disclosed herein that many modifications are possible without departing from the teachings hereof. All such modifications are intended to be encompassed within the following claims.

Claims
  • 1. A system for ablating uterine tissue comprising: a radio frequency (RF) ablation device comprising an elongate member and expandable applicator head coupled to a distal portion of the elongate member, the applicator head comprising a tissue contacting surface and an expandable-contractible carrying member, the carrying member having a contracted state and an expanded state, the contracted state being configured for transcervical insertion and the expanded state being configured for positioning the applicator head in contact with tissue to be ablated, the applicator head including one or more electrodes for ablating endometrial lining tissue of the uterus, the RF ablation device being configured to determine data related to the uterine cavity based on a degree of expansion of the carrying member when in the expanded configuration; andan RF generator, wherein when the RF generator is operably coupled to the RF ablation device, the RF generator is configured to receive the data from the RF ablation device and to provide an RF signal to the RF ablation device based on the data.
  • 2. The system of claim 1, wherein the applicator head comprises a plurality of flexures, wherein the RF ablation device is configured to determine dimensional data by transducing a distance of separation of two of the flexures.
  • 3. The system of claim 1 wherein the RF ablation device includes an indicator mechanism operatively coupled to the applicator head to indicate the degree of expansion of the applicator head.
  • 4. The system of claim 3 wherein the indicator mechanism is mechanically operatively coupled to the applicator head.
  • 5. The system of claim 3 wherein the indicator mechanism is electrically operatively coupled to the applicator head.
  • 6. The system of claim 1 wherein the expandable applicator head includes a plurality of flexures configured to move the applicator head from the contracted configuration to the expanded configuration, and wherein the RF ablation device includes a sensor configured to sense the degree of expansion of the applicator head, and wherein the sensor is configured sense movement of the flexures.
  • 7. The system of claim 1 wherein the RF ablation device includes a sensor for sensing the degree of expansion of the applicator head.
  • 8. The system of claim 1 wherein the RF ablation device is configured to electrically transmit the data to the RF generator.
  • 9. The system of claim 1 wherein the RF ablation device is configured to electrically transmit the data to a visual display.
  • 10. The system of claim 1 wherein the data includes a width of the uterine cavity.
CLAIM OF PRIORITY

This application is a continuation of U.S. application Ser. No. 13/423,908 filed Mar. 19, 2012, which is a continuation of U.S. application Ser. No. 12/775,752 filed May 7, 2010, now abandoned, which is a divisional of U.S. application Ser. No. 11/211,016, filed Aug. 24, 2005, now issued as U.S. Pat. No. 7,717,909, which is a divisional of U.S. application Ser. No. 10/328,447, filed Dec. 23, 2002, now issued as U.S. Pat. No. 7,074,217, which is a divisional of U.S. application Ser. No. 09/306,480, filed May 6, 1999, now issued as U.S. Pat. No. 6,508,815, which claims the benefit of Provisional Application 60/084,712, filed May 8, 1998, all of which are hereby incorporated herein by reference.

US Referenced Citations (271)
Number Name Date Kind
552832 Fort Jan 1896 A
725731 Linn Apr 1903 A
1620929 Wallerich Mar 1927 A
1827306 Chapman et al. Oct 1931 A
2190383 Newman Feb 1940 A
2347195 Huff Apr 1944 A
2466042 Reich et al. Apr 1949 A
3228398 Leonard et al. Jan 1966 A
3324855 Heimlich Jun 1967 A
3645265 Majzlin Feb 1972 A
3706307 Hasson Dec 1972 A
3840016 Lindemann Oct 1974 A
3845771 Vise Nov 1974 A
3858586 Lessen Jan 1975 A
3877464 Vermes Apr 1975 A
3924628 Droegemueller et al. Dec 1975 A
3948270 Hasson Apr 1976 A
3967625 Yoon Jul 1976 A
3971378 Krantz Jul 1976 A
4016867 King et al. Apr 1977 A
4022215 Benson May 1977 A
4057063 Gieles et al. Nov 1977 A
4082096 Benson Apr 1978 A
4094320 Newton et al. Jun 1978 A
4158050 Zipper Jun 1979 A
4185618 Corey Jan 1980 A
4224951 Hasson Sep 1980 A
4233025 Larson et al. Nov 1980 A
4347842 Beale Sep 1982 A
4359454 Hoffman Nov 1982 A
4380238 Colucci et al. Apr 1983 A
4415288 Gordon et al. Nov 1983 A
4449528 Auth et al. May 1984 A
4465072 Taheri Aug 1984 A
4489732 Hasson Dec 1984 A
4492231 Auth Jan 1985 A
4532483 Schminke Jul 1985 A
4532924 Auth et al. Aug 1985 A
4552557 Rangaswamy Nov 1985 A
4568326 Rangaswamy Feb 1986 A
4582057 Auth et al. Apr 1986 A
4601698 Moulding, Jr. Jul 1986 A
4606336 Zeluff Aug 1986 A
4628924 Cimber Dec 1986 A
4662383 Sogawa et al. May 1987 A
4676258 Inokuchi et al. Jun 1987 A
4685474 Kurz et al. Aug 1987 A
4691703 Auth et al. Sep 1987 A
4700701 Montaldi Oct 1987 A
4739759 Rexroth et al. Apr 1988 A
4765331 Petruzzi et al. Aug 1988 A
4788966 Yoon Dec 1988 A
4807620 Strul et al. Feb 1989 A
4832048 Cohen May 1989 A
4865047 Chou et al. Sep 1989 A
4869268 Yoon Sep 1989 A
4946440 Hall Aug 1990 A
4949718 Neuwirth et al. Aug 1990 A
4955377 Lennox et al. Sep 1990 A
4960133 Hewson Oct 1990 A
4961435 Kitagawa et al. Oct 1990 A
4979948 Geddes et al. Dec 1990 A
4981465 Ballan et al. Jan 1991 A
4983177 Wolf Jan 1991 A
5026379 Yoon Jun 1991 A
5047028 Qian Sep 1991 A
5057106 Kasevich et al. Oct 1991 A
5065751 Wolf Nov 1991 A
5078717 Parins et al. Jan 1992 A
5084044 Quint Jan 1992 A
5105808 Neuwirth et al. Apr 1992 A
5109869 Buckley May 1992 A
5147353 Everett Sep 1992 A
5159925 Neuwirth et al. Nov 1992 A
5160334 Billings et al. Nov 1992 A
5178148 Lacoste et al. Jan 1993 A
5186181 Franconi et al. Feb 1993 A
5188122 Phipps et al. Feb 1993 A
5188602 Nichols Feb 1993 A
5217473 Yoon Jun 1993 A
5226908 Yoon Jul 1993 A
5242437 Everett et al. Sep 1993 A
5248312 Langberg Sep 1993 A
5263585 Lawhon et al. Nov 1993 A
5275610 Eberbach Jan 1994 A
5277201 Stern Jan 1994 A
5308327 Heaven et al. May 1994 A
5318532 Frassica Jun 1994 A
5322507 Costello et al. Jun 1994 A
5334193 Nardella Aug 1994 A
5334209 Yoon Aug 1994 A
5354295 Guglielmi et al. Oct 1994 A
5357956 Nardella Oct 1994 A
5358496 Ortiz et al. Oct 1994 A
5364393 Auth et al. Nov 1994 A
5370649 Gardetto et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5374283 Flick Dec 1994 A
5380317 Everett et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5385544 Edwards et al. Jan 1995 A
5395311 Andrews Mar 1995 A
5405322 Lennox et al. Apr 1995 A
5407071 Lawhon et al. Apr 1995 A
5423808 Edwards et al. Jun 1995 A
5433708 Nichols et al. Jul 1995 A
5437629 Goldrath Aug 1995 A
5443470 Stern et al. Aug 1995 A
5451204 Yoon Sep 1995 A
5474089 Waynant Dec 1995 A
5484400 Edwards et al. Jan 1996 A
5498261 Strul Mar 1996 A
5505730 Edwards Apr 1996 A
5507743 Edwards et al. Apr 1996 A
5514091 Yoon May 1996 A
5540655 Edwards et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5542916 Hirsch et al. Aug 1996 A
5558672 Edwards et al. Sep 1996 A
5562703 Desai Oct 1996 A
5562720 Stern et al. Oct 1996 A
5573533 Strul Nov 1996 A
5575788 Baker et al. Nov 1996 A
5588961 Leone et al. Dec 1996 A
5593404 Costello et al. Jan 1997 A
5599345 Edwards et al. Feb 1997 A
5599346 Edwards et al. Feb 1997 A
5609598 Laufer et al. Mar 1997 A
5613950 Yoon Mar 1997 A
5620481 Desai et al. Apr 1997 A
5649924 Everett et al. Jul 1997 A
5656013 Yoon Aug 1997 A
5658316 Lamond et al. Aug 1997 A
5667520 Bonutti Sep 1997 A
5697882 Eggers et al. Dec 1997 A
5702438 Avitall Dec 1997 A
5716343 Kriesel et al. Feb 1998 A
5722975 Edwards et al. Mar 1998 A
5730136 Laufer et al. Mar 1998 A
5730725 Yoon Mar 1998 A
5733252 Yoon Mar 1998 A
5769880 Truckai et al. Jun 1998 A
5779698 Clayman et al. Jul 1998 A
5797903 Swanson et al. Aug 1998 A
5800482 Pomeranz et al. Sep 1998 A
5807389 Gardetto et al. Sep 1998 A
5810847 Laufer et al. Sep 1998 A
5827273 Edwards Oct 1998 A
5843026 Edwards et al. Dec 1998 A
5843121 Yoon Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5865788 Edwards et al. Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5879348 Owens et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5885601 Sokal Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891134 Goble et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5897551 Everett et al. Apr 1999 A
5897553 Mulier et al. Apr 1999 A
5935123 Edwards et al. Aug 1999 A
5935137 Saadat et al. Aug 1999 A
5938660 Swartz et al. Aug 1999 A
5944715 Goble et al. Aug 1999 A
5954717 Behl et al. Sep 1999 A
5979446 Loy Nov 1999 A
5997534 Tu et al. Dec 1999 A
6002968 Edwards Dec 1999 A
6014589 Farley et al. Jan 2000 A
6033397 Laufer et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6041260 Stern et al. Mar 2000 A
6042596 Bonutti Mar 2000 A
6047700 Eggers et al. Apr 2000 A
6066139 Ryan et al. May 2000 A
6068613 Kriesel et al. May 2000 A
6068626 Harrington et al. May 2000 A
6071277 Farley et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6074386 Goble et al. Jun 2000 A
6077257 Edwards et al. Jun 2000 A
6096052 Callister et al. Aug 2000 A
6112123 Kelleher et al. Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6123702 Swanson et al. Sep 2000 A
6135997 Laufer et al. Oct 2000 A
6139527 Laufer et al. Oct 2000 A
6139546 Koenig et al. Oct 2000 A
6152899 Farley et al. Nov 2000 A
6159207 Yoon Dec 2000 A
6164280 Everett et al. Dec 2000 A
6165172 Farley et al. Dec 2000 A
6179832 Jones et al. Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6193713 Geistert et al. Feb 2001 B1
6197025 Grossi et al. Mar 2001 B1
6200312 Zikorus et al. Mar 2001 B1
6224591 Claren et al. May 2001 B1
6231496 Wilk et al. May 2001 B1
6231507 Zikorus et al. May 2001 B1
6234178 Goble et al. May 2001 B1
6237606 Zikorus et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6245065 Panescu et al. Jun 2001 B1
6245090 Gilson et al. Jun 2001 B1
6254601 Burbank et al. Jul 2001 B1
6258084 Goldman et al. Jul 2001 B1
6258085 Eggleston Jul 2001 B1
6263248 Farley et al. Jul 2001 B1
6277089 Yoon Aug 2001 B1
6293942 Goble et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6309384 Harrington et al. Oct 2001 B1
6315776 Edwards et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6346102 Harrington et al. Feb 2002 B1
6352549 Everett Mar 2002 B1
6364877 Goble et al. Apr 2002 B1
6369465 Swanson Apr 2002 B1
6395012 Yoon et al. May 2002 B1
6398780 Farley et al. Jun 2002 B1
6402742 Blewett et al. Jun 2002 B1
6428537 Swanson et al. Aug 2002 B1
6432116 Callister et al. Aug 2002 B1
6451015 Rittman, III et al. Sep 2002 B1
6475213 Whayne et al. Nov 2002 B1
6485487 Sherman Nov 2002 B1
6485500 Kokish et al. Nov 2002 B1
6490474 Willis et al. Dec 2002 B1
6508815 Strul et al. Jan 2003 B1
6554780 Sampson et al. Apr 2003 B1
6663626 Truckai et al. Dec 2003 B2
6679269 Swanson Jan 2004 B2
6712810 Harrington et al. Mar 2004 B2
6712815 Sampson et al. Mar 2004 B2
6726682 Harrington et al. Apr 2004 B2
6743184 Sampson et al. Jun 2004 B2
6764488 Burbank et al. Jul 2004 B1
6813520 Sampson et al. Nov 2004 B2
6964274 Ryan et al. Nov 2005 B1
7074217 Strul et al. Jul 2006 B2
7407502 Strul et al. Aug 2008 B2
7512445 Truckai et al. Mar 2009 B2
7604633 Truckai et al. Oct 2009 B2
7717909 Strul May 2010 B2
7731712 Sampson et al. Jun 2010 B2
7846160 Payne et al. Dec 2010 B2
8551082 Strul Oct 2013 B2
20010041900 Callister et al. Nov 2001 A1
20020022870 Truckai et al. Feb 2002 A1
20020029051 Callister et al. Mar 2002 A1
20020072499 Clagett Jun 2002 A1
20020072745 Truckai et al. Jun 2002 A1
20020177846 Mulier et al. Nov 2002 A1
20030093101 O'Heeron et al. May 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030199863 Swanson et al. Oct 2003 A1
20040054368 Truckai et al. Mar 2004 A1
20040118166 Huang et al. Jun 2004 A1
20040172051 Ravikumar Sep 2004 A1
20040204720 Harrington et al. Oct 2004 A1
20040255958 Harrington et al. Dec 2004 A1
20050085880 Truckai et al. Apr 2005 A1
20050155608 Pavcnik et al. Jul 2005 A1
20050217680 Callister et al. Oct 2005 A1
20060135956 Sampson et al. Jun 2006 A1
20080071269 Hilario et al. Mar 2008 A1
20100036372 Truckai et al. Feb 2010 A1
20100217256 Strul et al. Aug 2010 A1
20120179155 Strul et al. Jul 2012 A1
Foreign Referenced Citations (29)
Number Date Country
1060594 Apr 1992 CN
384246 Oct 1923 DE
22 22 820 Nov 1973 DE
40 01 086 Jul 1991 DE
0 056 178 Apr 1981 EP
0 584 930 Jul 1993 EP
1 400 182 Mar 2004 EP
1 568 325 Aug 2005 EP
774 550 Dec 1934 FR
2 115 706 Jul 1972 FR
2 317 566 Apr 1998 GB
48-67586 Dec 1971 JP
58-32756 Feb 1983 JP
63-318934 Dec 1988 JP
9219145 Nov 1992 WO
9400178 Jan 1994 WO
9407445 Apr 1994 WO
9410948 May 1994 WO
9423794 Oct 1994 WO
9504385 Feb 1995 WO
9505869 Mar 1995 WO
9507664 Mar 1995 WO
9510326 Apr 1995 WO
9600042 Jan 1996 WO
9712569 Apr 1997 WO
9741785 Nov 1997 WO
9838932 Sep 1998 WO
9958070 Nov 1999 WO
0197897 Dec 2001 WO
Non-Patent Literature Citations (15)
Entry
“Essure, Permanent Birth Control by Conceptus: What is Essure?” Product Information Sheet [on-line] [retrieved Oct. 19, 2004] Retrieved from the Internet: < URL: http://www.essure.com/consumer/c.sub.--what.sub.--is.sub.--essure.aspx >.
“Essure: the non-incisional approach to permanent birth control”, Patient Information Booklet, .COPYRGT. 2004 by Conceptus Incorporated.
“Tubal Ligation and Resection: Tubal Ligation by Parkland and Irving Methods” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--resection.htm >.
“Tubal Ligation Methods: Coagulation Methods of Tubal Ligation” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004, [retrieved Oct. 19, 2004] Retrieved from the Internet: < http://www.tubal-reversal.net/tubal.sub.--ligation. sub.--coagulation.htm >.
“Tubal Ligation—Fimbriectomy: Tubal Reversal is Possible after Fimbriectomy” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--fimbriectomy.htm >.
“Tubal Ligation—Pomeroy Technique: Pomeroy Tubal Ligation and Resection” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004 ] Retrieved from the Internet: < http://www.tubal-reversal.net/print/printer-friendly-tubal.sub.--ligation- .sub.--Pomeroy.htm >.
“Tubal Ligation—Tubal Ring or Clip: Tubal Ligation with Tubal Rings or Tubal Clips” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/tubal.sub.--ligation-tubal.sub.--ring-tubal- .sub.--clip.htm >.
Adiana options for women—how it works. (Dec. 31, 2005). Retrieved from http://web.archive.org/web/20051124001429/www.adiana.com/products.sub.--h- ow.php.
C. Nibley et al., “Prevention of Impedance Rise During Radiofrequency Current Catheter Ablation by Intra-Electrode Tip Chilling,” Circulation [Abstracts From the 67th Scientific Sessions, Dallas Convention Center, Dallas, Texas, Nov. 14-17, 1994], vol. 90, No. 4, Part 2, Oct. 1994, p. 460.
D.E. Haines et al., “Observations on Electrode-Tissue Interface Temperature and Effect on Electrical Impedance During Radiofrequency Ablation of Ventricular Myocardium,” Circulation, vol. 82, No. 3, Sep. 1990, pp. 1034-1038.
METI-MyriadLase, SteriLase, Powerpoint Presentation, published at least as of Jun. 13, 2006, 6 pp.
W.M. Jackman et al., “Radiofrequency Current Directed Across the Mitral Anulus With a Bipolar Epicardial-Endocardial Catheter Electrode Configuration in Dogs,” Circulation, vol. 78, No. 5, Nov. 1988, pp. 1288-1298.
First Request for Ex Partes Reexamination of U.S. Pat. No. 5,769,880, filed Jul. 27, 1999, U.S. Appl. No. 90/005,435.
Second Request for Ex Partes Reexamination of U.S. Pat. No. 5,769,880, filed Nov. 22, 2000, U.S. Appl. No. 90/005,866.
Office Action mailed Mar. 6, 2015, U.S. Appl. No. 13/962,178, filed Aug. 8, 2013 in Re: Csaba Truckai, “Moisture Transport System for Contact Electrocoagulation”.
Related Publications (1)
Number Date Country
20140039482 A1 Feb 2014 US
Provisional Applications (1)
Number Date Country
60084712 May 1998 US
Divisions (3)
Number Date Country
Parent 11211016 Aug 2005 US
Child 12775752 US
Parent 10328447 Dec 2002 US
Child 11211016 US
Parent 09306480 May 1999 US
Child 10328447 US
Continuations (2)
Number Date Country
Parent 13423908 Mar 2012 US
Child 14046002 US
Parent 12775752 May 2010 US
Child 13423908 US